

# Merus

## Merus to Report First Quarter 2017 Financial & Mid-Year Operating Results on July 11, 2017

July 6, 2017

**Conference call and webcast scheduled on 4:30pm ET**

UTRECHT, The Netherlands, July 06, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclomics®), today announced that the company will provide a mid-year update on recent operating progress and report its first quarter 2017 financial results on July 11, 2017. Management will host a conference call and webcast at 4:30 pm ET.

To participate in the call, please dial (646) 722-4972 (domestic) or (866) 978-9968 (international) and reference conference ID 98331903. A live webcast will be available on the Investors page of the Company's website, <http://www.merus.nl>. An archived presentation will be available for 90 days.

### **About Merus N.V.**

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclomics®. Biclomics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is expected to begin a Phase 2 clinical trial in the second half of 2017 in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in Europe in gastric, ovarian, endometrial and non-small cell lung cancers. Merus' second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as MCLA-145 designed to bind to PD-L1 and a non-disclosed second immunomodulatory target, which is being developed in collaboration with Incyte.

Contacts:

Media:

Eliza Schleifstein  
+1 973 361 1546  
[eliza@argotpartners.com](mailto:eliza@argotpartners.com)

Investors:

Kimberly Minarovich  
+1 646 368 8014  
[kimberly@argotpartners.com](mailto:kimberly@argotpartners.com)

Merus N.V.